BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 31, 2002
View Archived Issues
SuperGen Starts Rolling NDA For Pancreatic Cancer Therapy
Coming in a few days under the wire, SuperGen Inc. said it has begun the rolling submission of a new drug application for Orathecin (rubitecan), an oral chemotherapy drug for refractory pancreatic cancer patients. (Bioworld Today)
Read More
CV Therapeutics Submits NDA Seeking Approval Of Ranolazin
Read More
Applied Biosystems Cutting Work Force, Plans R&D Boost
Read More
Amphora Adds $23M In Series B To Carry Out Discovery Programs
Read More
Holiday Notice
Read More
Other News To Note
Read More